X

Trial Profile

Multicenter Retrospective Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/darunavir (Primary) ; Dolutegravir; Rilpivirine
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms CoDAR

Most Recent Events

27 Jan 2021 Results (n=725) assessing changes in creatinine estimated glomerular filtration rate, published in the Journal of Antimicrobial Chemotherapy.
05 Oct 2019 Results determining the characteristics of darunavir/cobicistat use in HIV-infected adults in Spain published in the Journal of Antimicrobial Chemotherapy
24 Jun 2019 Results published in the Journal of Antimicrobial Chemotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com